Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Assisted Reproductive Technology (ART) Market Size & Share 2026-2035
Report ID: GMI506
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Assisted Reproductive Technology (ART) Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Assisted Reproductive Technology (ART) Market Size
The assisted reproductive technology (ART) market was valued at USD 38.9 billion in 2025, is projected to reach USD 42.2 billion in 2026, and is forecast to grow at a 7.7% CAGR (2026-2035) to USD 81.45 billion by 2035. The market encompasses clinical treatment, fertility pharmaceuticals, laboratory systems and consumables, preservation services, and genetic testing delivered through specialized clinics, hospitals, and cryobanks.
Assisted Reproductive Technology (ART) Market Key Takeaways
Market Leader: Ferring Pharmaceuticals led with over 5.4% market share in 2025.
Leading Players: Top 5 players in this market include Ferring Pharmaceuticals, Merck KGaA, IVI-RMA Global, CooperSurgical Fertility, Vitrolife Group, which collectively held a market share of 15.3% in 2025.
Market expansion is being shaped by later family formation, broader infertility diagnosis, and a shift from stand-alone treatment cycles toward technology-intensive care pathways. Reimbursement reforms are converting unmet need into clinic enrollment, while embryo assessment, vitrification, and genetic testing raise laboratory intensity and expand the value captured within each patient journey.
GMI Analyst View
Based on our review of verified annual performance data across fertility clinic chains, pharmaceutical companies, and laboratory product suppliers, the global ART market generated USD 35.52 billion in 2024. We view this historic revenue base as evidence that current expansion reflects broad demand across care delivery, medicines, and laboratory infrastructure rather than an isolated treatment-volume event.
Assisted Reproductive Technology (ART) Market Trends, Growth Drivers & GMI Forecast Outlook
The market's outlook rests on a reinforcing interaction between clinical need, access policy, and laboratory modernization. Broader coverage can move diagnosed patients into treatment, while more capable embryology workflows improve the commercial viability of specialized care models and support investment in differentiated ART capacity.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Infertility prevalence creates a demand pool that is not confined to affluent markets, but clinical conversion remains highly sensitive to awareness, affordability, and local treatment capacity. Providers that can shorten the path from diagnosis to specialist consultation are positioned to capture demand that historically remained outside formal fertility care.
Insurance integration has particular commercial significance because it changes both the timing and continuity of treatment. When coverage reduces initial financial friction, patients are more likely to begin care earlier and remain engaged through clinically appropriate treatment pathways, supporting utilization across procedures, medicines, testing, and preservation services.
Laboratory modernization is also altering the economic composition of treatment. Vitrification allows stimulation, testing, and transfer timing to be separated more deliberately, while AI-supported assessment can help clinic networks standardize workflows across sites. The resulting investment cycle favors operators and suppliers able to embed technology into repeatable clinical protocols.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Clinical efficacy constraints are especially consequential for patients who present later in their reproductive years. Repeat treatment may sustain revenue per enrolled patient, but unsuccessful cycles can also exhaust financial resources and emotional tolerance, limiting the volume ceiling among cohorts with growing need for fertility care.
Affordability remains a decisive gatekeeper in markets without broad reimbursement. Employer fertility benefits can support utilization among covered workers, yet they do not resolve access gaps for patients outside formal employment or in insurance arrangements that exclude ART. This produces uneven demand conversion even where specialist capacity is available.
Regulatory variation further shapes the procedure mix that individual markets can retain. Restrictions on donation, surrogacy, and genetic testing can redirect patients to permissive jurisdictions, creating concentrated opportunities for cross-border providers while constraining domestic premium-service expansion.
GMI Analyst View
We see access policy and clinical technology as distinct growth mechanisms that increasingly operate together. Coverage expansion unlocks patient volume, whereas laboratory differentiation increases the value and consistency of care once patients enter the system. The strongest operators will be those that can translate both forces into integrated treatment pathways rather than relying on a single procedure category.
Assisted Reproductive Technology (ART) Market Segment Analysis
By Sub-Market (Component)
ART Clinical Services
The assisted reproductive technology (ART) market's clinical services sub-market generated USD 18.7 billion in 2025 and is projected to account for 41.0% of global ART revenue by 2035. Clinics remain the principal point of patient engagement, but their commercial role is evolving from procedure delivery toward coordination of medicines, laboratory services, preservation, and follow-on transfer pathways.
Fertility Pharmaceuticals
Fertility pharmaceuticals represented 16.4% of global ART revenue in 2025 and are projected to reach USD 12.5 billion by 2035. The category's demand remains closely tied to stimulation and support protocols, although biosimilar competition and reimbursement design will influence how much cycle expansion translates into revenue growth.
Fertility Preservation Services
Fertility preservation services generated USD 4.7 billion in 2025 and are forecast to expand at an 11.7% CAGR (2026-2035). Elective preservation, medically indicated cryopreservation, and recurring storage relationships give this segment a more durable revenue profile than single-event treatment categories.
ART Lab Products & Equipment
ART lab products and equipment held 11.6% of global ART revenue in 2025 and are projected to reach USD 9.8 billion by 2035. Greater use of vitrification, incubation, micromanipulation, and digital embryo assessment is increasing the laboratory content of each treatment pathway and favoring suppliers with validated workflow integration.
Diagnostics & Genetic Testing (PGT)
Diagnostics and genetic testing generated USD 1.75 billion in 2025 and are forecast to grow at a 13.5% CAGR (2026-2035). The HFEA found that PGT-A use among UK fertility patients increased from 7% in 2021 to 13% in 2024, illustrating how genetic testing is moving closer to routine decision support in established fertility settings [2]Human Fertilisation & Embryology Authority. "National Patient Survey 2024." hfea.gov.uk. Adoption will remain linked to clinician confidence, laboratory capability, and the regulatory boundaries governing test use.
Other Ancillary Services
Other ancillary services accounted for 7.3% of global ART revenue in 2025 and are projected to generate USD 5.35 billion by 2035. This category benefits from demand for donor coordination and complementary services embedded in care pathways, although its trajectory remains dependent on local regulation and clinic service models.
By Procedure
IVF/ICSI - Fresh Cycle
IVF/ICSI fresh cycles generated USD 14.0 billion in 2025 and are projected to account for 27.1% of global ART revenue by 2035. Their relative position is being reshaped by clinical preference for separating stimulation from transfer, particularly where testing and cryopreservation are integrated into standard practice.
IVF/ICSI - Frozen Embryo Transfer (FET)
IVF/ICSI frozen embryo transfer represented 32.1% of global ART revenue in 2025 and is forecast to grow at an 8.5% CAGR (2026-2035). Improved vitrification and the flexibility to coordinate transfer timing with diagnostic and endometrial considerations are making FET central to more segmented, laboratory-intensive treatment protocols.
Fertility Preservation (Oocyte/Sperm/Embryo)
Fertility preservation procedures accounted for 12.1% of global ART revenue in 2025 and are projected to reach USD 14.2 billion by 2035. The procedure category is supported by elective oocyte freezing, medical preservation needs, and employer-supported access, while its longer-term value is reinforced by subsequent storage and transfer activity.
IUI / Artificial Insemination
IUI and artificial insemination generated USD 3.9 billion in 2025 and are projected to represent 7.2% of global ART revenue by 2035. The procedure retains an important lower-complexity role, but its relative trajectory is moderated where insurance and clinical practice patterns support earlier progression to IVF.
Others (Donor Programs, Surrogacy, etc.)
Other procedures, including donor programs and surrogacy-linked services, represented 9.8% of global ART revenue in 2025 and are forecast to grow at an 11.2% CAGR (2026-2035). Demand is concentrated in jurisdictions that permit these pathways and in cross-border patient flows from markets where domestic options are limited.
By End-Use
Fertility Clinics & Specialized ART Centers
Fertility clinics and specialized ART centers accounted for 75.0% of global ART revenue in 2025 and are projected to generate USD 61.09 billion by 2035. Their position reflects the specialized embryology infrastructure, physician expertise, and compliance systems required to manage complex treatment pathways at scale.
Hospitals
Hospitals generated USD 6.24 billion in 2025 and are projected to account for 15.6% of global ART revenue by 2035. Hospital-based programs remain relevant in academic and integrated-care settings, but specialist clinic networks often hold an advantage in patient experience, dedicated laboratory investment, and focused fertility care operations.
Cryobanks
Cryobanks represented 4.0% of global ART revenue in 2025 and are forecast to grow at a 9.5% CAGR (2026-2035). Expanding inventories of stored gametes and embryos create an annuity-like storage base, while donor demand and preservation adoption require continuing investment in capacity and quality systems.
Others
Other end-use settings generated USD 1.92 billion in 2025 and are projected to reach USD 3.79 billion by 2035. These providers serve localized ART demand where specialized clinics, hospitals, and cryobanks do not fully define the care-delivery model.
GMI Analyst View
We believe the market is moving toward care models in which clinical outcomes and laboratory capability are commercially inseparable. Providers that combine treatment delivery with strong embryology, preservation, and testing capabilities can offer more coherent patient pathways, while suppliers that fit into those workflows gain a more defensible role in clinic purchasing decisions.
Assisted Reproductive Technology (ART) Market Regional Analysis
North America Assisted Reproductive Technology (ART) Market Analysis
The assisted reproductive technology (ART) market in North America represented 29.0% of global revenue in 2025 and is projected to reach USD 22.19 billion by 2035. The region combines high-value private care, mature specialist-clinic infrastructure, and growing employer support, but its expansion remains constrained by uneven reimbursement across jurisdictions.
United States
The United States generated USD 10.94 billion in 2025 and is projected to reach USD 21.52 billion by 2035. SART recorded 425,869 total ART cycles nationally in its final 2023 report, underscoring the scale of the underlying treatment base [4]Society for Assisted Reproductive Technology. "Final National Summary Report for 2023." sartcorsonline.com. Employer-sponsored benefits and state-level coverage policy will remain important determinants of whether medically eligible patients can enter and continue care.
Canada
Canada's ART market benefits from provincial public funding programs in Quebec and Ontario that cover a defined number of IVF cycles, creating a partially insured patient pool that underpins more stable utilization relative to fully private-pay markets.
Europe Assisted Reproductive Technology (ART) Market Analysis
Europe generated USD 9.33 billion in 2025 and is projected to account for 21.5% of global ART revenue by 2035. Its market structure is defined by differing national rules on donor programs, PGT, and surrogacy, which sustain cross-border patient flows and create divergent commercial opportunities among otherwise mature healthcare systems.
Germany
Germany generated USD 1.49 billion in 2025 and is projected to reach USD 2.80 billion by 2035. Its regulatory environment limits several premium ART pathways, leaving legislative and reimbursement developments central to the market's ability to capture demand that may otherwise move to neighboring jurisdictions.
Spain
Spain generated USD 1.21 billion in 2025 and is projected to reach USD 2.27 billion by 2035. The country's permissive framework for donation and its established clinic base support its role as a destination for cross-border care, particularly for patients seeking services unavailable in their home markets.
United Kingdom
The United Kingdom generated USD 1.02 billion in 2025 and is projected to account for 11.0% of European ART revenue by 2035. HFEA oversight supports a transparent clinical environment, while regional variation in public funding sustains a substantial role for private fertility providers.
France
France's ART market benefits from broad public reimbursement of IVF cycles, supporting stable procedure volumes and high utilization rates relative to GDP. Regulatory restrictions on commercial surrogacy and egg donation from anonymous donors constrain the domestic premium-procedure market.
Italy
Italy's ART regulation has evolved to permit preimplantation genetic diagnosis and heterologous fertilization. Public regional health systems provide partial reimbursement, and private clinic chains have expanded capacity.
Asia Pacific Assisted Reproductive Technology (ART) Market Analysis
Asia Pacific accounted for 39.0% of global ART revenue in 2025 and is forecast to grow at a 9.5% CAGR (2026-2035). China's reimbursement expansion, Japan's established coverage framework, and private-clinic capacity growth across India and South Korea create a broad regional growth base with distinct national demand models.
China
China generated USD 7.58 billion in 2025 and is projected to reach USD 22.0 billion by 2035. ART insurance integration across provincial-level regions has made reimbursement a central demand catalyst, supporting capacity planning and earlier treatment access in a market where demographic policy and fertility care are increasingly connected [3]Xinhua News Agency. "China Focus: Lower costs, higher hopes: China's assisted fertility coverage eases the way to parenthood." english.news.cn.
Japan
Japan represented 16.0% of Asia Pacific ART revenue in 2025 and is forecast to grow at a 7.5% CAGR (2026-2035). National coverage has supported treatment access, while the country's dense fertility-clinic ecosystem and established clinical infrastructure provide a platform for sustained, technology-led care delivery.
India
India generated USD 1.36 billion in 2025 and is forecast to grow at an 11.9% CAGR (2026-2035). Its opportunity is anchored in large unmet demand, rapidly expanding clinic networks, and a regulatory framework that supports more formalized investment in ART delivery.
South Korea
South Korea generated USD 1.06 billion in 2025 and is projected to reach USD 2.2 billion by 2035. Pronatalist policy, financial support for fertility treatment, and advanced clinic laboratory practices support continuing adoption despite the country's demanding demographic backdrop.
Australia
Australia's ART market benefits from partial Medicare reimbursement of IVF cycles and a regulated, data-transparent clinical environment. Storage capacity constraints are emerging at leading clinic networks.
Latin America Assisted Reproductive Technology (ART) Market Analysis
Latin America represented 5.0% of global ART revenue in 2025 and is projected to reach USD 4.4 billion by 2035. Demand is primarily private-pay, making affordability and urban clinic access important constraints, while comparatively permissive rules in selected markets support regional medical tourism.
Brazil
Brazil generated USD 973 million in 2025 and is projected to reach USD 2.2 billion by 2035. Demand is concentrated in major urban centers, where private providers compete on clinical quality, patient experience, and access to donor-related services.
Mexico
Mexico is the second-largest Latin American ART market, with procedure volume concentrated in Mexico City and Guadalajara. The absence of a national ART regulation creates a relatively open operating environment for fertility clinics, attracting U.S. patients seeking cost-competitive IVF and donor procedures.
Middle East & Africa (MEA) Assisted Reproductive Technology (ART) Market Analysis
Middle East & Africa generated USD 1.16 billion in 2025 and is forecast to grow at a 9.0% CAGR (2026-2035). Healthcare investment, rising specialist capacity, and pronatalist policy support growth, although restrictions on donor gametes, surrogacy, and eligible patient groups limit the range of procedures available in many markets.
Israel
Israel generated USD 233 million in 2025 and is projected to reach USD 552 million by 2035. Broad public support for fertility treatment underpins a mature clinical ecosystem and makes reimbursement continuity a defining feature of domestic ART utilization.
Saudi Arabia
Saudi Arabia generated USD 210 million in 2025 and is projected to reach USD 497 million by 2035. The market is developing alongside healthcare-sector investment and expanding reproductive medicine capacity, within a regulatory framework that limits ART to eligible married couples.
UAE
The UAE generated USD 187 million in 2025 and is projected to account for 16.0% of MEA ART revenue by 2035. Advanced clinic infrastructure and medical-tourism demand position Dubai and Abu Dhabi as regional treatment hubs, while international network investment is increasing the market's operational sophistication.
GMI Analyst View
We expect regional performance to depend less on infertility need alone than on the ability of healthcare systems to convert need into treatment. Markets that align reimbursement, clinic capacity, and regulatory clarity can capture both domestic demand and cross-border patient flows, whereas fragmented access structures will continue to leave considerable demand untreated.
Assisted Reproductive Technology (ART) Market Share & Competitive Landscape
The global assisted reproductive technology (ART) market exhibits a fragmented competitive structure, with Ferring Pharmaceuticals, Merck KGaA (Fertility Division), IVI-RMA Global, CooperSurgical Fertility, and Vitrolife Group collectively accounting for approximately 15.3% of total market revenue in 2025. Competitive dynamics vary considerably across the ART value chain, with fertility clinics and treatment services remaining highly localized, while fertility pharmaceuticals, embryology laboratory products, genetic testing solutions, and assisted reproduction technologies are characterized by higher qualification barriers, technological complexity, and long-term supplier relationships. Market participants compete based on clinical outcomes, laboratory performance, product reliability, physician engagement, and the ability to support increasingly sophisticated fertility treatment protocols.
Thermo Fisher Scientific supports the market through life sciences products used in cell culture, cryopreservation, and laboratory instrumentation, while Hamilton Thorne specializes in precision embryology systems used for procedures such as embryo biopsy, assisted hatching, and advanced laboratory imaging. Additional companies including Esco Micro, Kitazato, NidaCon International, and Laboratoire CCD contribute through specialized solutions spanning vitrification systems, sperm-processing technologies, laboratory equipment, and fertility pharmaceutical distribution. Their competitive relevance is supported by validated product performance, technical support capabilities, and strong relationships within highly regulated laboratory environments.
Recent Industry Developments
In November 2025, IVI RMA Global completed its acquisition of ART Fertility Clinics' UAE operations, establishing the Middle East as an operating region for the reproductive medicine network. The transaction signals continued international consolidation among fertility-care platforms and increases the strategic importance of Gulf clinical infrastructure within cross-border ART delivery [6]IVI RMA Global / BusinessWire. "IVI RMA Global Establishes Middle East as Fifth Region with Acquisition of ART Fertility Clinics." businesswire.com.
In October 2026, Overture Life launched its ICSI.A robot-assisted fertilization system in U.S. IVF laboratories following FDA establishment registration and device listing. The development highlights the movement of IVF laboratory automation from early clinical deployment toward commercial use, with implications for workflow consistency and capacity management in multi-site clinic networks [7]Overture Life / BusinessWire. "Overture Life Brings Robot-Assisted Fertilization Technology to U.S. IVF Clinics with ICSI.A Launch." businesswire.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →